BR112015007866A2 - combinação de opióides e fármacos anticancerígenos para o tratamento do câncer. - Google Patents
combinação de opióides e fármacos anticancerígenos para o tratamento do câncer.Info
- Publication number
- BR112015007866A2 BR112015007866A2 BR112015007866A BR112015007866A BR112015007866A2 BR 112015007866 A2 BR112015007866 A2 BR 112015007866A2 BR 112015007866 A BR112015007866 A BR 112015007866A BR 112015007866 A BR112015007866 A BR 112015007866A BR 112015007866 A2 BR112015007866 A2 BR 112015007866A2
- Authority
- BR
- Brazil
- Prior art keywords
- opioids
- combination
- cancer treatment
- anticancer drugs
- anticancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12006946 | 2012-10-08 | ||
EP12007179.0A EP2716291B1 (en) | 2012-10-08 | 2012-10-17 | Combination of opioids and anticancer drugs for cancer treatment |
PCT/EP2013/070923 WO2014056897A1 (en) | 2012-10-08 | 2013-10-08 | Combination of opioids and anticancer drugs for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015007866A2 true BR112015007866A2 (pt) | 2017-08-08 |
Family
ID=47046323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015007866A BR112015007866A2 (pt) | 2012-10-08 | 2013-10-08 | combinação de opióides e fármacos anticancerígenos para o tratamento do câncer. |
Country Status (12)
Country | Link |
---|---|
US (2) | US20150265594A1 (pt) |
EP (1) | EP2716291B1 (pt) |
JP (1) | JP6472750B2 (pt) |
CN (1) | CN104902897A (pt) |
BR (1) | BR112015007866A2 (pt) |
CA (1) | CA2887043C (pt) |
DK (1) | DK2716291T3 (pt) |
ES (1) | ES2779223T3 (pt) |
PL (1) | PL2716291T3 (pt) |
PT (1) | PT2716291T (pt) |
RU (1) | RU2015114786A (pt) |
WO (1) | WO2014056897A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
WO2016090092A1 (en) * | 2014-12-03 | 2016-06-09 | Nemucore Medical Innovations, Inc. | Therapeutic nanoemulsions for delivery to and imaging of the brain and methods of their preparation and use |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US20190388499A1 (en) * | 2017-01-20 | 2019-12-26 | University Of Kansas | Macrocyclic peptides to decrease c-myc protein levels and reduce cancer cell growth |
CA3049464A1 (en) * | 2017-02-14 | 2018-08-23 | Research Triangle Institute | Proline-based neuropeptide ff receptor modulators |
AU2019216522A1 (en) * | 2018-02-05 | 2020-08-27 | Alkermes, Inc. | Compounds for the treatment of pain |
WO2019197015A1 (en) * | 2018-04-09 | 2019-10-17 | Peter Truog | Composition comprising 4-phenylbutyric acid derivatives & opioids |
CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
CN111920709A (zh) * | 2019-05-13 | 2020-11-13 | 帕芙姆斯得科尔有限公司 | 液体化妆品 |
WO2020239948A1 (en) | 2019-05-28 | 2020-12-03 | Isanas Ag | A CENTRALLY ACTING µ-OPIOID RECEPTOR AGONIST IN COMBINATION WITH A CURCUMINOID FOR USE IN THE TREATMENT OF A TUMOUR OF THE CENTRAL NERVOUS SYSTEM |
CN110638802A (zh) * | 2019-10-22 | 2020-01-03 | 深圳承启生物科技有限公司 | Atca在制备治疗肿瘤的药物中的用途 |
CN114113603B (zh) * | 2021-06-30 | 2023-11-17 | 四川大学华西医院 | Cytl1作为胃癌预后标志物的应用 |
CN117442737B (zh) * | 2023-11-01 | 2024-07-09 | 河北医科大学口腔医院 | α2-肾上腺素受体激动剂与阿片受体激动剂的联合应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9814036D0 (en) * | 1998-06-29 | 1998-08-26 | Univ Dundee | Materials and methods relating to the induction of apoptosis in target cells |
US7923454B2 (en) * | 2002-05-17 | 2011-04-12 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
EP1732583A4 (en) * | 2004-02-26 | 2009-08-12 | Penn State Res Found | COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS |
US8148338B2 (en) * | 2006-02-22 | 2012-04-03 | Supratek Pharma Inc. | Doxorubicin formulations for anti-cancer use |
CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
PT2149372E (pt) * | 2008-07-31 | 2014-07-25 | Universität Ulm | Utilização de opióides do grupo da metadona para o tratamento de pacientes com cancros resistentes |
-
2012
- 2012-10-17 DK DK12007179.0T patent/DK2716291T3/da active
- 2012-10-17 ES ES12007179T patent/ES2779223T3/es active Active
- 2012-10-17 PL PL12007179T patent/PL2716291T3/pl unknown
- 2012-10-17 PT PT120071790T patent/PT2716291T/pt unknown
- 2012-10-17 EP EP12007179.0A patent/EP2716291B1/en active Active
-
2013
- 2013-10-08 WO PCT/EP2013/070923 patent/WO2014056897A1/en active Application Filing
- 2013-10-08 JP JP2015535060A patent/JP6472750B2/ja active Active
- 2013-10-08 US US14/434,138 patent/US20150265594A1/en not_active Abandoned
- 2013-10-08 RU RU2015114786A patent/RU2015114786A/ru unknown
- 2013-10-08 CA CA2887043A patent/CA2887043C/en active Active
- 2013-10-08 CN CN201380060492.7A patent/CN104902897A/zh active Pending
- 2013-10-08 BR BR112015007866A patent/BR112015007866A2/pt not_active Application Discontinuation
-
2018
- 2018-06-05 US US16/000,467 patent/US11052082B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11052082B2 (en) | 2021-07-06 |
JP2015532298A (ja) | 2015-11-09 |
JP6472750B2 (ja) | 2019-02-20 |
ES2779223T3 (es) | 2020-08-14 |
CN104902897A (zh) | 2015-09-09 |
DK2716291T3 (da) | 2020-03-02 |
EP2716291B1 (en) | 2019-11-27 |
US20150265594A1 (en) | 2015-09-24 |
RU2015114786A (ru) | 2016-11-27 |
WO2014056897A1 (en) | 2014-04-17 |
US20180280380A1 (en) | 2018-10-04 |
CA2887043C (en) | 2021-06-22 |
PL2716291T3 (pl) | 2020-06-15 |
PT2716291T (pt) | 2020-03-04 |
EP2716291A1 (en) | 2014-04-09 |
CA2887043A1 (en) | 2014-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015007866A2 (pt) | combinação de opióides e fármacos anticancerígenos para o tratamento do câncer. | |
ZA201505735B (en) | Cancer drug and uses | |
IL276300A (en) | GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer | |
HUE042081T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
HK1221424A1 (zh) | 治療癌症的藥物組合 | |
SG2014008304A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
EP2818483A4 (en) | MEDICINAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
BR112016027041A2 (pt) | Combinações farmacêuticas para tratamento do câncer | |
HK1223304A1 (zh) | 包含二甲雙胍和二氫槲皮素的藥物組合及其用於治療癌症的用途 | |
IL243171A0 (en) | Polymeric nanoparticles of docetaxel for use in cancer treatment | |
HK1214128A1 (zh) | 癌症的治療 | |
HK1222548A1 (zh) | 治療惡性腫瘤的藥物組合 | |
GB201217892D0 (en) | Treatment of cancer | |
EP2962693A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CANCER | |
BR112014031785A2 (pt) | composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
HK1204956A1 (en) | Treatment of cancer | |
SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
GB201303184D0 (en) | Treatment of cancer | |
EP2949326A4 (en) | MOLECULAR FIXED COMBINATION ACTIVE FOR TUMOR THERAPY AND PREVENTION | |
BR112014028306A2 (pt) | métodos para tratamento de câncer gástrico. | |
GB201217890D0 (en) | Treatment of cancer | |
AU2013904239A0 (en) | Pharmaceutical combinations for the treatment of cancer | |
IL232339A0 (en) | 32rf10c antibodies, and their uses for cancer treatment | |
GB201322346D0 (en) | Combination treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |